Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial-Reference-Cited by-同舟云学术

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

Published:2015-10 Issue:10 Volume:2 Page:e417-e426
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Paton Nicholas I,Stöhr Wolfgang,Arenas-Pinto Alejandro,Fisher Martin,Williams Ian,Johnson Margaret,Orkin Chloe,Chen Fabian,Lee Vincent,Winston Alan,Gompels Mark,Fox Julie,Scott Karen,Dunn David T

Funder

National Institute for Health Research Health Technology Assessment programme

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference35 articles.

1. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012;Williams;HIV Med,2012

2. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel;Thompson;JAMA,2012

3. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance;Rabi;J Clin Invest,2013

4. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial;Ghosn;HIV Med,2010

5. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis;Arribas;J Acquir Immune Defic Syndr,2009

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT);eClinicalMedicine;2024-03

2. Peripheral Neuropathy in Virologically Suppressed People Living with HIV: Evidence from the PIVOT Trial;Viruses;2023-12-19

3. Enhancing the stability of antimicrobial peptides: From design strategies to applications;Chemical Engineering Journal;2023-11

4. Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance;eLife;2023-03-15

5. Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus;Medicine;2022-12-09